Ryder Honors Top Carriers of the Year for Commitment to Innovation and Service Excellence
MIAMI–(BUSINESS WIRE)–#RyderEverbetter—Ryder System, Inc. (NYSE: R), a leader in supply chain, dedicated transportation, and fleet management solutions,... Read more.
AECOM selected to provide engineering services for Metro Vancouver’s Stoney Creek Trunk Sewer Upgrade
New sewer pipeline will address sewerage and drainage needs for the Metro Vancouver region DALLAS–(BUSINESS WIRE)–AECOM (NYSE: ACM), the world’s... Read more.
Merck to Participate in the UBS BioPharma Conference
RAHWAY, N.J.–(BUSINESS WIRE)–$MRK #MRK–Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Jannie Oosthuizen,... Read more.
Assured Guaranty Ltd. Declares Quarterly Dividend of $0.28 per Common Share
HAMILTON, Bermuda–(BUSINESS WIRE)–Assured Guaranty Ltd. (NYSE:AGO) today declared a quarterly dividend of $0.28 per common share. The dividend is payable... Read more.
Karuna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2023 Neuroscience Education Institute Congress
Analyses of pooled efficacy data from the EMERGENT program demonstrate significant improvements in schizophrenia symptoms Analyses extend prior findings that KarXT... Read more.
Materion Corporation Reports Record Third Quarter 2023 Results
MAYFIELD HEIGHTS, Ohio–(BUSINESS WIRE)–Materion Corporation (NYSE: MTRN) today reported third quarter financial results and affirmed the midpoint of... Read more.
Ferguson plc: Block Listing Six Monthly Return
WOKINGHAM, England–(BUSINESS WIRE)– Name of applicant: Ferguson plc Name of scheme: Ferguson Group International Sharesave Plan 2011 Period of... Read more.
ATS to Participate in the Baird 2023 Global Industrial Conference
CAMBRIDGE, Ontario–(BUSINESS WIRE)–ATS Corporation (TSX and NYSE: ATS) (“ATS” or the “Company”), an industry-leading automation... Read more.
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Gemcitabine and Cisplatin as Treatment for Patients With Locally Advanced Unresectable or Metastatic Biliary Tract Cancer
Approval based on results from the Phase 3 KEYNOTE-966 trial, which demonstrated significant overall survival benefit in these patients versus chemotherapy alone... Read more.
The Estée Lauder Companies Reports Fiscal 2024 First Quarter Results
Net Sales Decreased 10% and Diluted EPS Declined to $.09 Organic Net Sales1 Declined 11% and Adjusted Diluted EPS Decreased to $.11 Delivered First Quarter Expectations... Read more.